Northern Trust Corp Geron Corp Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Geron Corp stock. As of the latest transaction made, Northern Trust Corp holds 5,134,403 shares of GERN stock, worth $19 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,134,403
Previous 4,740,272 8.31%
Holding current value
$19 Million
Previous $20.1 Million 15.98%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$4.17 - $4.99 $1.64 Million - $1.97 Million
394,131 Added 8.31%
5,134,403 $23.3 Million
Q2 2024

Aug 14, 2024
SELL
$3.1 - $5.09 $893,714 - $1.47 Million
-288,295 Reduced 5.73%
4,740,272 $20.1 Million
Q1 2024

May 14, 2024
SELL
$1.75 - $3.44 $156,044 - $306,737
-89,168 Reduced 1.74%
5,028,567 $16.6 Million
Q4 2023

Feb 13, 2024
SELL
$1.74 - $2.31 $419,853 - $557,391
-241,295 Reduced 4.5%
5,117,735 $10.8 Million
Q3 2023

Nov 13, 2023
BUY
$2.11 - $3.28 $280,733 - $436,400
133,049 Added 2.55%
5,359,030 $11.4 Million
Q2 2023

Aug 11, 2023
BUY
$1.97 - $3.69 $1.94 Million - $3.63 Million
983,740 Added 23.19%
5,225,981 $16.8 Million
Q1 2023

May 15, 2023
BUY
$2.14 - $3.4 $1.31 Million - $2.09 Million
614,165 Added 16.93%
4,242,241 $9.21 Million
Q4 2022

Feb 13, 2023
BUY
$2.03 - $2.42 $240,843 - $287,113
118,642 Added 3.38%
3,628,076 $8.78 Million
Q3 2022

Nov 14, 2022
SELL
$1.67 - $2.94 $209,795 - $369,340
-125,626 Reduced 3.46%
3,509,434 $8.21 Million
Q2 2022

Aug 12, 2022
BUY
$1.19 - $1.65 $772,832 - $1.07 Million
649,439 Added 21.75%
3,635,060 $5.64 Million
Q1 2022

May 13, 2022
SELL
$0.99 - $1.6 $91,871 - $148,478
-92,799 Reduced 3.01%
2,985,621 $4.06 Million
Q4 2021

Feb 08, 2022
SELL
$1.22 - $1.72 $112,831 - $159,074
-92,485 Reduced 2.92%
3,078,420 $3.76 Million
Q3 2021

Nov 15, 2021
BUY
$1.2 - $1.5 $18,826 - $23,533
15,689 Added 0.5%
3,170,905 $4.34 Million
Q2 2021

Aug 13, 2021
BUY
$1.25 - $1.83 $167,378 - $245,042
133,903 Added 4.43%
3,155,216 $4.45 Million
Q1 2021

May 12, 2021
SELL
$1.52 - $2.1 $301,631 - $416,728
-198,442 Reduced 6.16%
3,021,313 $4.77 Million
Q4 2020

Feb 11, 2021
SELL
$1.55 - $2.05 $172,555 - $228,218
-111,326 Reduced 3.34%
3,219,755 $5.12 Million
Q3 2020

Nov 16, 2020
BUY
$1.59 - $2.19 $1.13 Million - $1.56 Million
713,774 Added 27.27%
3,331,081 $5.8 Million
Q2 2020

Aug 14, 2020
BUY
$1.05 - $2.18 $338,926 - $703,675
322,787 Added 14.07%
2,617,307 $5.71 Million
Q1 2020

May 14, 2020
BUY
$0.89 - $1.49 $92,810 - $155,378
104,281 Added 4.76%
2,294,520 $2.73 Million
Q4 2019

Feb 14, 2020
BUY
$1.27 - $1.54 $90,846 - $110,160
71,533 Added 3.38%
2,190,239 $2.98 Million
Q3 2019

Nov 13, 2019
BUY
$1.15 - $1.59 $61,818 - $85,470
53,755 Added 2.6%
2,118,706 $2.82 Million
Q2 2019

Aug 13, 2019
SELL
$1.37 - $2.02 $123,930 - $182,729
-90,460 Reduced 4.2%
2,064,951 $2.91 Million
Q1 2019

May 13, 2019
SELL
$1.01 - $1.83 $12,669 - $22,955
-12,544 Reduced 0.58%
2,155,411 $3.58 Million
Q4 2018

Feb 12, 2019
BUY
$0.98 - $1.85 $104,319 - $196,928
106,448 Added 5.16%
2,167,955 $2.17 Million
Q3 2018

Nov 14, 2018
BUY
$1.76 - $6.38 $142,547 - $516,735
80,993 Added 4.09%
2,061,507 $3.63 Million
Q2 2018

Sep 18, 2018
SELL
$3.29 - $4.82 $16,683 - $24,442
-5,071 Reduced 0.26%
1,980,514 $6.79 Million
Q2 2018

Aug 14, 2018
BUY
$3.29 - $4.82 $613,904 - $899,397
186,597 Added 10.37%
1,985,585 $6.81 Million
Q1 2018

May 09, 2018
SELL
$1.81 - $5.98 $72,497 - $239,522
-40,054 Reduced 2.18%
1,798,988 $7.65 Million
Q4 2017

Feb 14, 2018
SELL
$1.8 - $2.32 $39,213 - $50,541
-21,785 Reduced 1.17%
1,839,042 $3.31 Million
Q3 2017

Nov 13, 2017
BUY
$1.99 - $2.65 $3.7 Million - $4.93 Million
1,860,827
1,860,827 $4.06 Million

Others Institutions Holding GERN

# of Institutions
273
Shares Held
491M
Call Options Held
1.62M
Put Options Held
670K
View Full List

About GERON CORP

GERN Quotes by TradingView
  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.4B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email